Remimazolam, Body Composition
Conditions
Brief summary
Remimazolam is a novel general anesthetic drug. The time to emergence from remimazolam-based general anesthesia is variable among patients, but little is known about the risk factors for delayed emergence. We believe that information from body composition analysis may be helpful in understanding which patients are more likely to show delayed emergence from remimazolam.
Interventions
Body composition analysis by bioelectrical impedance measurement, just before induction of anesthesia.
Sponsors
Samsung Medical Center
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult ASA I-III patients undergoing cerebral aneurysm coil embolization under general anesthesia using remimazolam
Exclusion criteria
* Patients with preoperative mental change, hemodynamic instability, hemodialysis, heart failure, hypoalbuminemia, pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| emergence time | at the time of emergence | relationship between body composition analysis information and time to emergence after discontinuing remimazolam infusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| time to loss of consciousness | at the time of induction | relationship between body composition analysis information and time to loss of consciousness after starting remimazolam infusion. |
| hypotension | from induction to emergence of anesthesia | relationship between body composition analysis information and hypotensive event during anesthesia |
Countries
South Korea
Outcome results
None listed